Lindsey Shapiro, PhD, science writer —

Treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) led to gains in body mass among cystic fibrosis (CF) patients that were largely driven by increases in various types of fat and low-density muscles, a study found. High-density muscle, which is stronger than its lower-density counterparts, didn’t change with the treatment, sold as…

In lab studies, researchers have identified rare mutations in the CFTR gene — which are the cause of cystic fibrosis (CF) — that are not currently eligible for CFTR modulator therapies but might be treatment responsive. The researchers hope the findings will provide guidance to developer Vertex Pharmaceuticals…

Doctors should take care not to oversimplify when talking to patients about treatment decisions for chronic illnesses, according to patients, caregivers, and physicians interviewed for a study focusing on CFTR modulator therapy for cystic fibrosis (CF). It’s also important to have “compassionate conversations” with patients who aren’t eligible…

Gut bacteria called Bacteroides had anti-inflammatory effects in the blood and airways of a mouse model of cystic fibrosis (CF) via its production of an immune-modulating metabolite called propionate, a study finds. The findings add to evidence of a so-called gut-lung axis, where microbes in the gut can influence…

Stopping treatment with inhaled supportive therapies hypertonic saline (HS) or Pulmozyme (dornase alfa) didn’t negatively affect airway mucus clearance among cystic fibrosis (CF) patients with mild lung disease who were being also treated with Trikafta (elexacaftor/tezacaftor/ivacaftor), a report suggests. Indeed, the findings from the six-week study…

ReCode Therapeutics has launched a Phase 1 clinical trial to evaluate the safety of RCT2100, its investigational genetic medicine for  cystic fibrosis (CF), in healthy volunteers and the first group of participants has been dosed. RCT2100 is being developed for CF patients with class I mutations in the…

Treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor), sold in the U.S. as Trikafta, reduced signs of sinus disease, as seen on MRI scans, among children with cystic fibrosis (CF), according to new research from Germany. Improvements were seen on the children’s imaging scans regardless of whether they had never before used…

Adults with cystic fibrosis (CF) make as much use of most routine preventive healthcare services as adults in the general population, and in some cases more than they do, according to a recent analysis of U.S. insurance claims data. This services — of growing importance as CFTR modulator…

The diversity and relative abundance of microbes in the lungs — or the lung microbiome — was generally stable over an eight-month period in people with cystic fibrosis (CF), regardless of whether they had experienced a pulmonary exacerbation, according to a recent study. In the short term, using…

A high burden of infection-causing bacteria persisted in the lungs of people with cystic fibrosis (CF) who were treated with Trikafta (elexacaftor/tezacaftor/ivacaftor) in a recent study, despite an increase in the overall diversity of microbes and improvements in lung function being seen. The changing dynamics of this microbial…